With the objective to develop a potential ^99mTc radiopharmaceutical for imaging the androgen receptor (AR) in prostate cancer, four ligands bearing the same pharmacophore derived from the AR antagonist flutamide were prepared, labeled with ^99mTc, and their structures corroborated via comparison with the corresponding stable rhenium analogs. All complexes were obtained with high radiochemical purity. Three of the complexes were highly stable, and, due to their favorable physicochemical properties, were further evaluated using AR-positive and AR-negative cells in culture. All complexes exhibited considerable uptake in AR-positive cells, which could be blocked by an excess of flutamide. The efflux from the cells was moderate. They also showed significantly lower uptakes in AR-negative cells, indicating interactions with the AR receptor. However, the binding affinities were considerably reduced by the coordination to ^99mTc, and the complex that exhibited the best biological behavior did not show sufficient specificity towards AR-positive cells.

“Click reactions” are a very useful tool for the selective conjugation of different molecular subunits to produce complex structures in a simple way. In this paper, we present the application of Cu(I)-catalyzed biorthogonal reactions between alkynes and azides to the indirect radiofluorination of an estradiol derivative with potential applications in estrogen receptor imaging. The procedure was fully developed on an automated synthesis platform, and conditions were optimized to achieve the desired product with a reasonable yield without precipitation. Although the biological results were not adequate for a potential radiopharmaceutical, the outcome of this work is valuable since the use of automated platforms is required for the reliable and reproducible preparation of PET radiopharmaceuticals in GMP conditions while limiting the radiation dose rates to the personnel.

The advent of the Sustainable Development Goals (SDGs) by the United Nations (UN) in 2015 has redefined global development priorities, emphasizing the intertwined objectives of eradicating poverty, ensuring health, and promoting environmental sustainability. This review critically examines the role of radiopharmaceuticals and nuclear medicine in advancing these goals, particularly SDG 3 (Good Health and Well-being). Radiopharmaceuticals and nuclear medicine provide unparalleled precision in diagnosing and treating various diseases, including cancer, cardiovascular, and neurological disorders, thus enhancing global health outcomes and reducing healthcare disparities. Despite their transformative potential, integrating these technologies into global health systems faces significant challenges. Key among these are issues of accessibility and affordability, especially in low- and middle-income countries and environmental sustainability concerns related to the production and disposal of radioactive materials. Addressing these challenges is imperative to align with SDG 12 and SDG 13. Future directions for the field must prioritize innovation, sustainability, and international collaboration. This includes the development of novel radiopharmaceuticals with improved diagnostic and therapeutic efficacy, adopting environmentally friendly synthesis methods, and harmonising regulatory frameworks to facilitate global accessibility. Strengthening global partnerships and enhancing capacity building through targeted educational initiatives are essential to bridge the gap between high-income and low-income regions. In conclusion, radiopharmaceuticals and nuclear medicine are poised to be critical components in achieving the UN' SDGs. These technologies can significantly impact global health, foster socio-economic growth, and contribute to a sustainable and equitable future through concerted efforts in innovation, sustainable practices, and international cooperation.